Children who achieved a first remission with difficulty and those receiving regular vincristine and prednisolone in their first remission were less likely to achieve a second remission. Those who failed to go back into remission with the more commonly used drugs were not usually responsive to other drugs.
. However, there is less agreement about the management of the many children who relapse while on treatment. Cornbleet & Chessells (1978) (Cornbleet & Chessells, 1978; Rivera et al., 1976; Aur et al., 1972; Jacquillat et al., 1973; Leventhal et al., 1975; George et al., 1979) . As (Peto et al., 1976 (Peto et al., , 1977 . We studied survival from relapse, the proportion of children achieving a second remission and the durations of the second haematological and complete remissions.
RESULTS
Four of the 190 children studied (2-1 %) had relapsed with a non-lymphoblastic leukaemia. The overall probability of achieving a second remission was 49-1 % (Fig. 1) attain a second remission (P < 0-020'$ < 0-005 respectively). (Greaves et al., 1975 (Cornbleet & Chessells, 1978; George et al., 1979) . From our study it can be said that marrow relapse on treatment has a uniformly fatal outcome. The 49% of children attaining a second remission in our series was a considerably smaller proportion than the 85% reported by Rivera et al. (1978) in 56 children relapsing on treatment. However, none of the children in their series had received vineristine and prednisolone pulses during remission maintenance; lack of exposure to these two drugs before relapse improved children's chances of a second remission in our series. If the addition of these drugs, as has been suggested (Aur et al., 1973; Simone, 1976) (Janossy et al., 1976 ).
We were not surprised to find differences in outcome between centres. The intensity of treatment given when the expected outlook is poor depends on the philosophy of the physician as well as the wishes of the child and family (Kearney, 1977 (Fig. 5) . This confirms the findings of others (George et al., 1979; MRC, 1977) (Simone et al., 1975 (Fig. 6 ). New approaches to treatment, such as marrow transplantation (Thomas, 1978) would seem justifiable in selected cases; but this is feasible for few children relapsing at present. The alternatives are palliative therapy or using protocols to test hypotheses about relapse. Prospective trials of asparaginase (Kung et al., 1978) , glutaminase (Spiers & Wade, 1976) , asparagine synthetase inhibitors (Uren et al., 1977) and high-dose methotrexate (Frei et al., 1975) 
